<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34921121</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF).</ArticleTitle><Pagination><StartPage>539</StartPage><EndPage>546</EndPage><MedlinePgn>539-546</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2021-328194</ELocationID><Abstract><AbstractText Label="BACKGROUND">Patients with amyotrophic lateral sclerosis (ALS) show considerable variation in symptoms. Treatments targeting an overall improvement in symptomatology may not address what the majority of patients consider to be most important. Here, we propose a composite endpoint for ALS clinical trials that weighs the improvement in symptoms compared with what the patient population actually wants.</AbstractText><AbstractText Label="METHODS">An online questionnaire was sent out to a population-based registry in The Netherlands. Patients with ALS were asked to score functional domains with a validated self-reported questionnaire, and rank the order of importance of each domain. This information was used to estimate variability in patient preferences and to develop the Patient-Ranked Order of Function (PROOF) endpoint.</AbstractText><AbstractText Label="RESULTS">There was extensive variability in patient preferences among the 433 responders. The majority of the patients (62.1%) preferred to prioritise certain symptoms over others when evaluating treatments. The PROOF endpoint was established by comparing each patient in the treatment arm to each patient in the placebo arm, based on their preferred order of functional domains. PROOF averages all pairwise comparisons, and reflects the probability that a patient receiving treatment has a better outcome on domains that are most important to them, compared with a patient receiving placebo. By means of simulation we illustrate how incorporating patient preference may upgrade or downgrade trial results.</AbstractText><AbstractText Label="CONCLUSIONS">The PROOF endpoint provides a balanced patient-focused analysis of the improvement in function and may help to refine the risk-benefit assessment of new treatments for ALS.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Eijk</LastName><ForeName>Ruben P A</ForeName><Initials>RPA</Initials><Identifier Source="ORCID">0000-0002-7132-5967</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Data Science and Centre for Innovative Study Design, Stanford University, Stanford, California, USA R.P.A.vanEijk-2@umcutrecht.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Centre, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>L H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Centre, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Data Science and Centre for Innovative Study Design, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA124435</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL089778</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003142</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol Neurosurg Psychiatry. 2022 May;93(5):457</RefSource><PMID Version="1">35022316</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057240" MajorTopicYN="Y">Patient Preference</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword><Keyword MajorTopicYN="N">randomised trials</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>18</Day><Hour>5</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34921121</ArticleId><ArticleId IdType="mid">NIHMS1793874</ArticleId><ArticleId IdType="pmc">PMC9016230</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2021-328194</ArticleId><ArticleId IdType="pii">jnnp-2021-328194</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Chalabi A, Hardiman O, Kiernan MC, et al. . Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol 2016;15:1182&#x2013;94. 10.1016/S1474-4422(16)30199-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30199-5</ArticleId><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. . Amyotrophic lateral sclerosis. Lancet 2017;390:2084&#x2013;98. 10.1016/S0140-6736(17)31287-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, de Jongh AD, Nikolakopoulos S, et al. . An old Friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener 2021;22:300&#x2013;7. 10.1080/21678421.2021.1879865</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1879865</ArticleId><ArticleId IdType="pubmed">33527843</ArticleId></ArticleIdList></Reference><Reference><Citation>
European Medicines Agency . Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis, 2016. Available: https://www.ema.europa.eu/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-amyotrophic-lateral-sclerosis_en.pdf [Accessed 04 May 2021].</Citation></Reference><Reference><Citation>
Food drug administration center for drugs evaluation research. guidance for industry: amyotrophic lateral sclerosis: developing drugs for treatment, 2019. Available: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM596718.pdf [Accessed 04 May 2021].</Citation></Reference><Reference><Citation>Fournier CN, Bedlack R, Quinn C, et al. . Development and validation of the Rasch-Built overall amyotrophic lateral sclerosis disability scale (roads). JAMA Neurol 2020;77:480&#x2013;8. 10.1001/jamaneurol.2019.4490</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.4490</ArticleId><ArticleId IdType="pmc">PMC6990811</ArticleId><ArticleId IdType="pubmed">31886839</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel V, Stewart SS, Smith G, et al. . A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987;22:328&#x2013;33. 10.1002/ana.410220308</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410220308</ArticleId><ArticleId IdType="pubmed">3118763</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchignoni F, Mandrioli J, Giordano A, et al. . A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:331&#x2013;7. 10.3109/21678421.2015.1026829</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1026829</ArticleId><ArticleId IdType="pubmed">25916346</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchignoni F, Mora G, Giordano A, et al. . Evidence of multidimensionality in the ALSFRS-R scale: a critical appraisal on its measurement properties using Rasch analysis. J Neurol Neurosurg Psychiatry 2013;84:1340&#x2013;5. 10.1136/jnnp-2012-304701</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-304701</ArticleId><ArticleId IdType="pubmed">23516308</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimura-Kiyono C, Kimura F, Ishida S, et al. . Onset and spreading patterns of lower motor neuron involvements predict survival in sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011;82:1244&#x2013;9. 10.1136/jnnp-2011-300141</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-300141</ArticleId><ArticleId IdType="pubmed">21921087</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol 2014;10:661&#x2013;70. 10.1038/nrneurol.2014.184</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Zhao Q, Zou J. A composite endpoint approach to evaluate treatment benefits based on patient preferences. Under review 2021.</Citation></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M. World Federation of Neurology Research group on motor neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman MHB, de Jong SW, van Doormaal PTC, et al. . Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry 2011;82:1165&#x2013;70. 10.1136/jnnp.2011.244939</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2011.244939</ArticleId><ArticleId IdType="pubmed">21622937</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker LA, Schr&#xf6;der CD, Tan HHG, et al. . Development and assessment of the inter-rater and intra-rater reproducibility of a self-administration version of the ALSFRS-R. J Neurol Neurosurg Psychiatry 2020;91:75&#x2013;81. 10.1136/jnnp-2019-321138</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-321138</ArticleId><ArticleId IdType="pubmed">31558653</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (phase III). J Neurol Sci 1999;169:13&#x2013;21. 10.1016/S0022-510X(99)00210-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakore NJ, Lapin BR, Kinzy TG, et al. . Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach. Amyotroph Lateral Scler Frontotemporal Degener 2018;19:483&#x2013;94. 10.1080/21678421.2018.1484925</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1484925</ArticleId><ArticleId IdType="pubmed">30001159</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Jones A, Jivraj N, et al. . Estimating clinical stage of amyotrophic lateral sclerosis from the ALS functional rating scale. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:279&#x2013;84. 10.3109/21678421.2014.897357</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.897357</ArticleId><ArticleId IdType="pubmed">24720420</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Moreno AC, van Overbeeke E, Pinto CA, et al. . Patient preferences in rare diseases: a qualitative study in neuromuscular disorders to inform a quantitative preference study. Patient 2021;14:601&#x2013;12. 10.1007/s40271-020-00482-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40271-020-00482-z</ArticleId><ArticleId IdType="pmc">PMC8357717</ArticleId><ArticleId IdType="pubmed">33660162</ArticleId></ArticleIdList></Reference><Reference><Citation>
Food Drug Administration Center for Drugs Evaluation Research . FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient&#x2019;s Voice in Medical Product Development and Regulatory Decision Making, 2020. Available: https://www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical [Accessed 30 August 2021].</Citation></Reference><Reference><Citation>
European Medicines Agency . Ich reflection paper on proposed ICH guideline work to advance patient focused drug development, 2020. Available: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-reflection-paper-proposed-ich-guideline-work-advance-patient-focused-drug-development_en.pdf [Accessed 30 Aug 2021].</Citation></Reference><Reference><Citation>Janssens R, Huys I, van Overbeeke E, et al. . Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review. BMC Med Inform Decis Mak 2019;19:189. 10.1186/s12911-019-0875-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-019-0875-z</ArticleId><ArticleId IdType="pmc">PMC6778383</ArticleId><ArticleId IdType="pubmed">31585538</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Miller R, Moore DH, et al. . The combined assessment of function and survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:162&#x2013;8. 10.3109/21678421.2012.762930</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.762930</ArticleId><ArticleId IdType="pubmed">23323713</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Nikolakopoulos S, Roes KCB, et al. . Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry 2019;90:1331&#x2013;7. 10.1136/jnnp-2019-320998</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320998</ArticleId><ArticleId IdType="pmc">PMC6902062</ArticleId><ArticleId IdType="pubmed">31292200</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;tavy F, Guizzaro L, Antunes Dos Reis I, et al. . Beyond "Intent-to-treat" and "Per protocol": Improving assessment of treatment effects in clinical trials through the specification of an estimand. Br J Clin Pharmacol 2020;86:1235&#x2013;9. 10.1111/bcp.14195</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.14195</ArticleId><ArticleId IdType="pmc">PMC7319001</ArticleId><ArticleId IdType="pubmed">31883123</ArticleId></ArticleIdList></Reference><Reference><Citation>Oude Rengerink K, Mitroiu M, Teerenstra S, et al. . Rethinking the intention-to-treat principle: one size does not fit all. J Clin Epidemiol 2020;125:198&#x2013;200. 10.1016/j.jclinepi.2020.04.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2020.04.023</ArticleId><ArticleId IdType="pubmed">32380178</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Rooney J, Hardiman O, et al. . Two heads are better than one: benefits of joint models for ALS trials. J Neurol Neurosurg Psychiatry 2019;90:1071&#x2013;2. 10.1136/jnnp-2019-320553</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320553</ArticleId><ArticleId IdType="pubmed">30975822</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeldman E, Govaarts R, de Visser M, et al. . Progression of cognitive and behavioural impairment in early amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2020;91:779&#x2013;80. 10.1136/jnnp-2020-322992</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322992</ArticleId><ArticleId IdType="pmc">PMC7361007</ArticleId><ArticleId IdType="pubmed">32404381</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Moglia C, Canosa A, et al. . Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology 2019;93:e984&#x2013;94. 10.1212/WNL.0000000000008063</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008063</ArticleId><ArticleId IdType="pmc">PMC6745732</ArticleId><ArticleId IdType="pubmed">31409738</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>